Cited by 89

The DOI matches its Crossref record.

Expression of the Very Low-Density Lipoprotein Receptor (VLDL-r), an Apolipoprotein-E Receptor, in the Central Nervous System and in Alzheimerʼs Disease

Christie, Richard H., Chung, Haeyong, Rebeck, G. William, Strickland, Dudley, Hyman, Bradley T.·1996·Journal of Neuropathology and Experimental Neurology

Abstract

The very low density lipoprotein receptor (VLDL-r) is a cell-surface molecule specialized for the internalization of multiple diverse ligands, including apolipoprotein E (apoE)-containing lipoprotein particles, via clathrin-coated pits. Its structure is similar to the low-density lipoprotein receptor (LDL-r), although the two have substantially different systemic distributions and regulatory pathways. The present work examines the distribution of VLDL-r in the central nervous system (CNS) and in relation to senile plaques in Alzheimer disease (AD). VLDL-r is present on resting and activated microglia, particularly those associated with senile plaques (SPs). VLDL-r immunoreactivity is also found in cortical neurons. Two exons of VLDL-r mRNA are differentially spliced in the mature receptor mRNA. One set of splice forms gives rise to receptors containing (or lacking) an extracellular O-linked glycosylation domain near the transmembrane portion of the molecule. The other set of splice forms appears to be brain-specific, and is responsible for the presence or absence of one of the cysteine-rich repeat regions in the binding region of the molecule. Ratios of the receptor variants generated from these splice forms do not differ substantially across different cortical areas or in AD. We hypothesize that VLDL-r might contribute to metabolism of apoE and apoE/A beta complexes in the brain. Further characterizations of apoE receptors in Alzheimer brain may help lay the groundwork for u…

Overview

Integrity signals

Registry

Crossref · 10.1097/00005072-199604000-00012

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Activated astrocytes used in the experiments express both LDLR and LRP by immunostaining.

    “By immunostaining, these activated astrocytes express both the LDLR and LRP (data not shown), consistent with the previous observations summarized above that these are the two primary members of the LDLR family that are expressed by activated astrocytes (4 -7, 29 -31).”
  • Neural cells express a variety of apoE receptors in the LDLR family.

    “neural cells express a variety of apoE receptors in the low density lipoprotein receptor (LDLR) family (4 -7).”

Citations

Cited by

Sorted by citations

Metadata

Authors
Christie, R. H., Chung, H., Rebeck, G. W., Strickland, D., & Hyman, B. T.
Venue
Journal of Neuropathology and Experimental Neurology
Published
1996-04
Volume
55
Issue
4
Pages
491
ISSN
0022-3069
Cited by
89
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review